Moderna (MRNA) Points to Study Making Case for Vaccine Booster Amid Waning Immunity
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Moderna, Inc. (Nasdaq: MRNA) reported new clinical data on its COVID-19 vaccine, highlighting the results of the vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC), a separate recent publication by the U.S. Centers for Disease Control and Prevention (CDC) and a new analysis of open-label portion of Phase 3 COVE study, showing lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) than participants vaccinated last year (median 13 months after first dose).
The Prospective Cohort Study at Kaiser Permanente Southern California, which analyzed 352,878 recipients of two doses of mRNA-1273 matched to 352,878 unvaccinated individuals, being conducted during the emergence of the Delta variant (identified in 47% of cases in fully vaccinated individuals), found a vaccine effectiveness of 87% against COVID-19 diagnosis and 96% against COVID-19 hospitalization.
The company also mentioned the study published last week by the U.S. Centers for Disease Control and Prevention, according to which Moderna's vaccine was 95% effective at preventing hospitalization among individuals of all ages compared with 80% for Pfizer/BioNTech and 60% for Johnson & Johnson.
The company’s new data from its large COVID-19 vaccine trial shows that the protection it offers declines over time, supporting the case for booster doses.
Stéphane Bancel, Chief Executive Officer of Moderna said that the findings related to waning immunity and the need for a booster dose may be helpful as health authorities and regulators continue to assess strategies for ending the pandemic.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Delaying Decision on Moderna (MRNA) Covid-19 Vaccine in Adolescents While Evaluating Myocarditis Risk - DJ
- Novavax (NVAX) Will Participate in World Vaccine Congress Europe
- Popular stocks with increasing volume: F DIS SPCE DKNG MRNA
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!